Show simple item record

dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorBilici, Ahmet
dc.contributor.authorEr, Özgür
dc.contributor.authorSevinç, Ali İbrahim
dc.contributor.authorAkman, Tülay
dc.contributor.authorUslu, Rüçhan
dc.contributor.authorMandel, Nil Molinas
dc.contributor.authorYalçın, Şule
dc.contributor.authorTeomete, Mehmet
dc.contributor.authorGörümlü, Gürbüz
dc.contributor.authorDemir, Ahmet Muzafer
dc.contributor.authorNamal, Esat
dc.contributor.authorAlıcı, Süleyman
dc.contributor.authorSelçukbiricik, Fatih
dc.contributor.authorBavbek, Sevil
dc.contributor.authorPaksoy, Fatma
dc.contributor.authorBaşaran, Gül
dc.contributor.authorÖzer, Leyla
dc.contributor.authorŞener, Nazlı
dc.contributor.authorHarputluoğlu, Hakan
dc.date.accessioned2020-10-30T09:50:24Z
dc.date.available2020-10-30T09:50:24Z
dc.date.issued2020en_US
dc.identifier.citationÖlmez, Ö. F., Bilici, A., Er, Ö., Sevinç, A. İ., Akman, T., Uslu, R. ... Harputluoğlu, H. (2020). The effect of the use of complex molecular profiling in advanced solid organ tumours on clinical decision: Turkey Molecular Profiling in Advanced Cancers Trial (TUMPACT). ESMO Virtual Congress içinde (S1120-S1120. ss.). Electrical Network, September 19-October 18, 2020. https://dx.doi.org/10.1016/j.annonc.2020.08.1314en_US
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.urihttps://dx.doi.org/10.1016/j.annonc.2020.08.1314
dc.identifier.urihttps://hdl.handle.net/20.500.12511/5994
dc.description.abstractBackground: Molecular genetic profiling (MGP) which has started to take an important part in cancer diagnosis and treatment in recent years, has entered the routineclinical practice much faster than expected. We aimed to evaluate the use of thistechnology in routine practice, the effect of changing the treatment decision.Methods: Two hundred and thirty-four patients who received treatment from 21different centers with OncoDeep MGP platform tests were included, which uses acombination of new generation sequencing (NGS), immunohistochemistry (IHC) andother specific tests (Package Plus).Results: Summary was given in the table. Physician waited for test results in 27%(n¼61) of patients for treatment decision. Prior to MGP analysis patients receivedmedian 2-lines of treatment. The median time between sending the sample abroadfor testing and reaching the result by the physician was 14 days (range:5-71). With thetest results, the physician changed the treatment decision in 51.8% of the patients(n¼118). The most frequent way of drug supply of patients whose treatment decisionwere 64.4% (n ¼ 67) from their own budget. When the treatment responses wereevaluated, the disease control rate was 31.1% and the drug discontinuation wasapplied due to toxicity in 4 patients (3.4%). 63.6% (n ¼ 75) of the patients were foundto be alive with a median follow-up of 18.0 months. (Table).en_US
dc.description.sponsorshipEuropean Society for Medical Oncologyen_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectTUMPACTen_US
dc.subjectOrgan Tumoursen_US
dc.subjectComplex Molecularen_US
dc.titleThe effect of the use of complex molecular profiling in advanced solid organ tumours on clinical decision: Turkey Molecular Profiling in Advanced Cancers Trial (TUMPACT)en_US
dc.typeconferenceObjecten_US
dc.relation.ispartofESMO Virtual Congressen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.identifier.volume31en_US
dc.identifier.issueSupplement: 4en_US
dc.identifier.startpageS1120en_US
dc.identifier.endpageS1120en_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1016/j.annonc.2020.08.1314en_US
dc.identifier.wosqualityQ1en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record